Acorda gets a badly needed PDUFA date with the FDA on Parkinson's drug; Takeda signs neurological collaboration with antisense player Wave Life Sciences
→ Acorda $ACOR says that the FDA has finally accepted their application for Inbrija (CVT-301), putting their inhaled form of levodopa for Parkinson’s on …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
